Optometry Times On the Air

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, retina specialist John Kitchens, MD, has a conversation with a patient about the choice he made for anti-VEGF therapy to reduce his treatment burden, then discusses recent clinical trial data on therapeutic options with extended treatment intervals.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Genentech, Inc.

Chair:

John Kitchens, MD
Retina Associates of Kentucky
Eye Care Partners

Disclosures: Advisor, Consultant, Fee for Service Recipient: Alcon, Apellis, Astellas, Bayer, Roche Speakers Bureau: Apellis, Astellas, Bayer, Roche, Regeneron Ownership in Public Traded Companies: Vortex Surgical

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on educating patients on their anti-VEGF options, go to https://www.gotoper.com/courses/reducing-treatment-burden-in-retinal-disease-care-with-extended-duration-anti-vegf-therapies.

Release Date

June 30, 2026

Expiration Date

June 30, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Francis Mah, MD; and Amy Nau, OD, FAAO, Dipl, CCLRT; discuss how to identify neurotrophic keratitis in practice, highlighting indications for corneal sensitivity testing based on patient history and examination findings. Faculty will also examine how to stage and treat neurotrophic keratitis once diagnosed.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Dompé US.

Faculty:

Francis Mah, MD

Director, Cornea Service
Co-Director, Refractive Surgery Service
Scripps Clinic Torrey Pines
La Jolla, CA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Alcon, Aperta, Azura, Bausch + Lomb, BioTissue, BVI, ClearSight, Evolve, Eyenovia, EyeYon, Glaukos, Invirsa, iView, Johnson & Johnson Vision, Kala Bio, Lenz Therapeutics, OcuTerra, OSRX, PMN, PolyActiva, Puget Sound Therapeutics, Signal12, Sophia Bio, STAAR, Sydnexis, Tarsus Pharmaceuticals, Viatris, Yuyu Pharma, Zeiss; Ownership Interests in Privately Held Companies: Avellino Group, Eyenovia, Horizon Surgical Systems, iView, Kala Bio, Okogen, OSRX, Puget Sound Therapeutics, Signal12, Sophia Bio, Sydnexis

Amy Nau, OD, FAAO, Dipl, CCLRT

Adjunct Associate Professor
New England College of Optometry
Co-Owner, Forefront Eye Care
Co-Founder/CEO, Eyewell
Boston, MA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: InMode; Speakers Bureau: Tarsus, Vital Tears; Equity Owner: Eyewell, Forefront Eye Care; Other: Educational Sponsorship: BioTissue, Dompé, Glaukos, InMode, LacriFill, Lumenis, Ocubio, RxSight

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER® editorial staff based on a live activity developed with this faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including clinical trial data of therapies used for neurotrophic keratitis, go to https://www.gotoper.com/courses/searching-for-silence-corneal-sensitivity-testing-in-nk-9b9i.

Release Date

June 15, 2026

Expiration Date

June 15, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description 

In this podcast, experts Charles C. Wykoff, MD, PhD, FASRS; Jed H. Assam, MD, MS; Diana V. Do, MD; and Dante Pieramici, MD, FASRS; discuss the diagnosis, clinical features, and evolving management strategies for patients diagnosed with macular telangiectasia (MacTel) type 2.

Learning Objectives 

Upon successful completion of this activity, you should be better prepared to:

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Neurotech Pharmaceuticals, Inc.

Faculty:

Charles C. Wykoff, MD, PhD, FASRS

Director of Research, Retina Consultants of Texas
Chairman of Research & Clinical Trials, Retina Consultants of America
Houston, TX

Disclosures: Consultant/Honoraria: 4DMT, AbbVie, Acuta, ADARx, Adverum, Alcon, Alimera, Alkeus, Allgenesis, AMC Sciences, Annexon, Apellis, Arrowhead, Ascidian, Astellas, Aviceda, Bausch + Lomb, Bayer, BioCryst, Bionic Vision, Boehringer Ingelheim, Chengdu Kanghong, Curacle, Emmecell, Eyebiotech, EyePoint, Genentech, InGel, Janssen, Kiora, Kodiak, Kowa, Nanoscope, Neurotech, NGM, Novartis, Oak Bay Bio, Ocular Therapeutix, OcuTerra, Ollin, ONL, Opthea, Opus, Osanni, Oxular, Palatin, Perceive Bio, Perfuse, Ray, Regeneron, Regenxbio, RetinAI, Roche, Samsung Bioepis, Sandoz, Sanofi, Santen, Skyline, Stealth, Sylentis, TCG Crossover, THEA, Therini, VH401,Visgenx, Zeiss; Research Grants: 4DMT, AbbVie, Adverum, AffaMed, Alexion, Alimera, Allgenesis, Amgen, Annexin, Annexon, Apellis, Ascidian, AsclepiX, Astellas, Aviceda, Avirmax, Bayer, Boehringer Ingelheim, Chengdu Origen, Clearside, Curacle, Eluminex, Eyebiotech, EyePoint, Genentech, IONIS, iRenix, Janssen, Kalaris, Kodiak, Kyoto DDD, Kyowa Kirin, Nanoscope, Neurotech, NGM, Novartis, Ocugen, Ocular Therapeutix, Oculis, OcuTerra, OliX, Ollin, Opthea, Outlook Therapeutics, Oxular, Oxurion, Perceive Bio, Pykus, Regeneron, Regenxbio, Rezolute, Roche, Shanghai Henlius, Stealth, Skyline, VH401; Stock Options (Not Owner) From Private For-Profit Entities: InGel, Ollin, ONL, Osanni, Panther, TissueGen, Visgenx, Vitranu

Diana V. Do, MD

Vice Chair of Clinical Affairs
Professor of Ophthalmology
The Byers Eye Institute
Stanford University School of Medicine
Palo Alto, CA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Apellis, Astellas, Belite Bio, LumiThera, Oculis, Regenxbio; Grant/Research Funding: Apellis, Belite Bio, LumiThera, Neurotech, Oculis, Regeneron, Regenxbio; Ownership Interests in Publicly-Traded Companies: Belite Bio, Kodiak Sciences

Dante Pieramici, MD, FASRS

Medical Director, Clinical Research, California Retina Consultants
Director, California Retina Research Foundation
Partner, California Retina Consultants/Retina Consultants of America
Santa Barbara, CA 

Disclosures: Advisory: Perceive; Consultant: 4DMT, Adverum, Eyepoint, Genentech, Neurotech, Ocular Therapeutix, Opthea, Regeneron, Retina AI, Roche, Samsung, Unity; Research Funding: 4DMT, Adverum, Eyepoint, Genentech, Novartis, Ocular, Ocular Therapeutix, Opthea, Regeneron, Retina AI, Roche; Unity

Jed H. Assam, MD

Clinical Faculty
Department of Surgery
University of South Dakota
Sanford School of Medicine
Sioux Falls, SD

Disclosures: Jed H. Assam, MD, has no relevant financial relationships with ineligible companies.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including the diagnosis and interdisciplinary management of MacTel, go to https://www.gotoper.com/courses/mactel-decoded-rethinking-conventional-approaches-with-novel-neuroprotective-strategies.

Release Date

January 30, 2026

Expiration Date

January 30, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description 

In this podcast, experts Janelle L. Davison, OD; Cecelia Koetting, OD, FAAO, DipABO; and Cory J. Lappin, OD, MS, FAAO; discuss neuromodulation as a treatment modality for dry eye disease, focusing on a novel thermoregulatory therapy.

Learning Objectives 

Upon successful completion of this activity, you should be better prepared to:

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Alcon Vision, Inc.

Faculty:

Janelle L. Davison, OD

Owner and Clinical Director
Brilliant Eyes Vision Center
Visionary Dry Eye Institute
Smyrna, GA

Disclosures: Janelle L. Davison, OD, has no relevant financial relationships with ineligible companies.

Cecelia Koetting, OD, FAAO, DipABO

Assistant Professor
Department of Ophthalmology
University of Colorado School of Medicine
Denver, CO

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie/Allergan, Alcon Inc, Bausch + Lomb, Dompé, Harrow, Movu, Myze, Orasis Pharmaceuticals, Tarsus Pharmaceuticals, Topcon, Viatris Inc, Visus; Grant/Research Funding: Kala Bio

Cory J. Lappin, OD, MS, FAAO

Founder
The Dry Eye Center of Ohio
Cincinnati, OH

Disclosures: Advisory Board, Consultant, Speaker: Alcon Inc; Barti; Bausch + Lomb; Bruder Healthcare and M&S Technologies (Hilco Vision); CSI Dry Eye Software; Dompé Pharmaceuticals; Eyederm; Eyenovia; Harrow, Inc; Lumenis; Myze; Nordic Pharma; Norwood Device & Diagnostics; NuLids; Ocubio; PRN Vision Group; Rinsada; SCOPE Health Inc; Sight Sciences; Tarsus Pharmaceuticals, Inc; TearRestore Inc; Viatris Inc (Oyster Point Pharma); Vital Tears LLC; Investment: Barti, Myze, NuLids; Ownership Stake: Eyederm; Executive Team Member: Myze; Medical Director: Norwood Device & Diagnostics

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including further data on neuromodulating dry eye therapies, go to https://www.gotoper.com/boston25optometry-ded-activity 

Release Date

January 30, 2026

Expiration Date

January 30, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Episode Description 

In this podcast, expert Mile Brujic, OD, FAAO, discusses the burden, diagnosis, and management of Demodex blepharitis, highlighting a recently approved targeted treatment option.

Learning Objectives 

Upon successful completion of this activity, you should be better prepared to:

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Tarsus Pharmaceuticals, Inc. 

Chair:

Mile Brujic, OD, FAAO

Premier Vision Group
Bowling Geen, OH

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: ABB Optical Group, AbbVie, Alcon, Apellis, Art Optical, Bausch + Lomb Health, Contamac, CooperVision, CS Eye, Dompé, Dopavision, Glaukos, Iveric Bio, Johnson & Johnson Vision Care, Lentechs, MDelite, Nordic Pharma, Notal Vision, Orasis, Radius XR, RVL, Sun Pharma, Tangible Science, Tarsus, Viatris, Visionix, Walman Optical, ZeaVision

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

Release Date

January 31, 2026

Expiration Date

January 31, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.